|
PT1037927E
(pt)
|
1997-12-08 |
2004-10-29 |
Emd Lexigen Res Ct Corp |
Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
|
|
WO2000058456A2
(en)
*
|
1999-03-30 |
2000-10-05 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinacious compounds
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
JP4793971B2
(ja)
|
1999-08-09 |
2011-10-12 |
メルク パテント ゲーエムベーハー |
複合サイトカイン−抗体複合体
|
|
AU2154401A
(en)
|
1999-11-12 |
2001-05-30 |
Merck Patent Gmbh |
Erythropoietin forms with improved properties
|
|
CA2399832C
(en)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
EP1935431A3
(en)
|
2000-05-15 |
2008-08-13 |
Health Research, Inc. |
Cancer treatments by using a combination of an antibody against her2 and interleukin-2
|
|
US6689353B1
(en)
*
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US7517526B2
(en)
|
2000-06-29 |
2009-04-14 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
|
US7723102B2
(en)
*
|
2000-09-28 |
2010-05-25 |
Bayer Corporation |
Enhanced transfection system
|
|
MY139948A
(en)
*
|
2000-09-28 |
2009-11-30 |
Bayer Corp |
Enhanced transfection system
|
|
CA2440221C
(en)
|
2001-03-07 |
2013-02-05 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
PL205352B1
(pl)
|
2001-05-03 |
2010-04-30 |
Merck Patent Gmbh |
Rekombinowane przeciwciało specyficzne dla nowotworu
|
|
DK1454138T3
(da)
|
2001-12-04 |
2012-02-13 |
Merck Patent Gmbh |
Immunocytokiner med moduleret selektivitet
|
|
PL211180B1
(pl)
|
2002-12-17 |
2012-04-30 |
Merck Patent Gmbh |
Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
|
|
US7569215B2
(en)
|
2003-07-18 |
2009-08-04 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
DK1648931T3
(da)
*
|
2003-07-21 |
2011-03-07 |
Transgene Sa |
Multifunktionelle cytokiner
|
|
DE602004031341D1
(de)
*
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
CA2544948A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Methods of therapy for cancers expressing the cd40 antigen
|
|
WO2005085282A1
(en)
*
|
2004-02-27 |
2005-09-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
|
|
RU2006135112A
(ru)
*
|
2004-03-05 |
2008-04-10 |
Чирон Корпорейшн (Us) |
Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
|
|
WO2009061853A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CN101244261B
(zh)
*
|
2008-03-10 |
2010-09-15 |
山东大学 |
一种含未复性重组蛋白的生物制剂及其制备方法与应用
|
|
DE102008023820A1
(de)
*
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
CA2749539C
(en)
|
2009-01-21 |
2022-07-19 |
Amgen Inc. |
Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases
|
|
CN102101885B
(zh)
*
|
2010-09-01 |
2013-06-05 |
南京发士达生物科技有限公司 |
低诱导抑制性t细胞的人白细胞介素ⅱ突变体及其用途
|
|
JP2014506116A
(ja)
|
2010-11-12 |
2014-03-13 |
ウェルズ ファーゴ バンク ナショナル アソシエイション |
Ｉｌ−２部分とポリマーとのコンジュゲート
|
|
CU23923B1
(es)
*
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
EP3211001B1
(en)
*
|
2010-12-22 |
2020-10-07 |
The Board of Trustees of the Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
ES2579987T3
(es)
|
2011-02-10 |
2016-08-18 |
Roche Glycart Ag |
Polipéptidos interleuquina-2 mutantes
|
|
WO2012119093A1
(en)
*
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
EA034350B1
(ru)
|
2014-02-06 |
2020-01-30 |
Ф.Хоффманн-Ля Рош Аг |
Слитые белки, содержащие интерлейкин-2, и их применения
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
CA2946398A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
PL3482766T3
(pl)
*
|
2014-08-11 |
2020-11-16 |
Delinia, Inc. |
Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
|
|
WO2016164937A2
(en)
*
|
2015-04-10 |
2016-10-13 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
|
CA3000211A1
(en)
|
2015-10-08 |
2017-04-13 |
Nektar Therapeutics |
Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CN109689694B
(zh)
*
|
2016-05-19 |
2022-11-22 |
通用医疗公司 |
与其受体IL-2Rβ结合的IL2作为用来增强自然杀伤细胞和调节性T细胞活性的平台
|
|
NZ789594A
(en)
|
2016-06-20 |
2025-07-25 |
Kymab Ltd |
Anti-PD-L1 antibodies
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
JP7206190B2
(ja)
*
|
2016-06-22 |
2023-01-17 |
ダヴィド・クラッツマン |
遺伝的に修飾されたｔリンパ球
|
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
BR122020025384B1
(pt)
*
|
2016-12-13 |
2022-07-12 |
Delinia, Inc |
Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
|
|
CA3056630A1
(en)
|
2017-03-15 |
2018-09-20 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
JP2020520665A
(ja)
|
2017-05-24 |
2020-07-16 |
ノバルティス アーゲー |
抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
|
|
CA3064435A1
(en)
|
2017-05-24 |
2018-11-29 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
EP3630162A1
(en)
*
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
|
CN111201035A
(zh)
|
2017-06-19 |
2020-05-26 |
梅迪塞纳医疗股份有限公司 |
Il-2超激动剂、激动剂及其融合体的用途和方法
|
|
AR112969A1
(es)
*
|
2017-08-03 |
2020-01-15 |
Synthorx Inc |
Conjugados de citoquina para el tratamiento de enfermedades proliferativas e infecciosas
|
|
EP3713592A4
(en)
*
|
2017-11-21 |
2022-01-12 |
The Board of Trustees of the Leland Stanford Junior University |
INTERLEUKIN-2 PARTIAL AGONISTS
|
|
US10174092B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
MA51291A
(fr)
|
2017-12-19 |
2020-10-28 |
Xencor Inc |
Protéines de fusion il-2 fc modifiées
|
|
US11534479B2
(en)
|
2018-02-16 |
2022-12-27 |
Iltoo Pharma |
Use of interleukin 2 for treating Sjögren's syndrome
|
|
TWI853807B
(zh)
|
2018-03-28 |
2024-09-01 |
美商必治妥美雅史谷比公司 |
介白素-2/介白素-2受體阿法融合蛋白及其使用方法
|
|
CA3093722A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma Oncology Division A/S |
Il-2 conjugates
|
|
WO2020007937A1
(en)
|
2018-07-03 |
2020-01-09 |
Iltoo Pharma |
Use of interleukin-2 for treating systemic sclerosis
|
|
KR20210038549A
(ko)
*
|
2018-07-24 |
2021-04-07 |
비온테크 알엔에이 파마슈티컬스 게엠베하 |
Il2 작용제
|
|
US12403181B2
(en)
|
2018-08-13 |
2025-09-02 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|
|
US11492384B2
(en)
*
|
2018-09-17 |
2022-11-08 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
TWI791894B
(zh)
|
2018-09-21 |
2023-02-11 |
大陸商信達生物製藥（蘇州）有限公司 |
新型白介素２及其用途
|
|
WO2020125743A1
(zh)
|
2018-12-21 |
2020-06-25 |
江苏恒瑞医药股份有限公司 |
一种人白细胞介素2变体或其衍生物
|
|
BR112021023345A2
(pt)
|
2019-05-20 |
2022-02-01 |
Pandion Operations Inc |
Imunotolerância com alvo em madcam
|
|
TW202115105A
(zh)
*
|
2019-06-24 |
2021-04-16 |
德商拜恩迪克Ｒｎａ製藥有限公司 |
Ｉｌ２激動劑
|
|
KR20220051177A
(ko)
|
2019-07-26 |
2022-04-26 |
비스테라, 인크. |
인터류킨-2 작용제 및 이의 용도
|
|
TW202120534A
(zh)
*
|
2019-08-13 |
2021-06-01 |
美商安進公司 |
用於擴增調節性ｔ細胞之介白素－２突變蛋白
|
|
CN115190885A
(zh)
|
2019-12-12 |
2022-10-14 |
艾尔图制药公司 |
白细胞介素2嵌合构建体
|
|
CA3162705A1
(en)
|
2019-12-17 |
2021-06-24 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
|
CA3162406A1
(en)
|
2020-01-10 |
2021-07-15 |
Vijaya Raghavan PATTABIRAMAN |
Modified il-2 polypeptides and uses thereof
|
|
US11491205B2
(en)
|
2020-01-14 |
2022-11-08 |
Synthekine, Inc. |
Biased IL2 muteins methods and compositions
|
|
MX2022008770A
(es)
*
|
2020-01-14 |
2022-10-07 |
Synthekine Inc |
Muteinas de la il2.
|
|
WO2021168079A1
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a cd39 effector
|
|
US20230145766A1
(en)
|
2020-03-19 |
2023-05-11 |
Innovent Biologics (Suzhou) Co., Ltd. |
Interleukin-2 mutant and use thereof
|
|
CN118271419A
(zh)
|
2020-03-31 |
2024-07-02 |
韩美药品株式会社 |
新型免疫刺激il-2类似物
|
|
US12428461B2
(en)
|
2020-06-03 |
2025-09-30 |
Ascendis Pharma Oncology Division A/S |
Treating cancer with a conjugate comprising an IL-2 moiety
|
|
IL302114A
(en)
|
2020-10-29 |
2023-06-01 |
Bristol Myers Squibb Co |
Fusion proteins for the treatment of disease
|
|
CN114507643A
(zh)
*
|
2020-10-29 |
2022-05-17 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-2的多能干细胞衍生物及应用
|
|
MX2023006599A
(es)
|
2020-12-04 |
2023-06-19 |
Visterra Inc |
Metodos de uso de agentes de interleucina-2.
|
|
CN113308477A
(zh)
*
|
2021-04-08 |
2021-08-27 |
华南农业大学 |
一种鸭il-2基因真核表达重组质粒及其制备方法
|
|
CA3233075A1
(en)
|
2021-09-22 |
2023-03-30 |
Fortvita Biologics (Singapore) Pte. Ltd. |
Interleukin-2 mutant and fusion protein thereof
|
|
KR20240113459A
(ko)
|
2021-10-06 |
2024-07-22 |
일투 파마 |
염증 조직에 대한 표적화 특이성을 갖는 인터루킨 2 키메라 구성체
|
|
CN114875069B
(zh)
*
|
2022-04-22 |
2023-09-15 |
四川大学 |
基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途
|
|
JP2025520544A
(ja)
|
2022-06-16 |
2025-07-03 |
セファロン エルエルシー |
抗ｐｄ１抗体－減弱ｉｌ２免疫複合体とその用途
|
|
CA3265946A1
(en)
|
2022-09-12 |
2024-03-21 |
Univ Sorbonne |
INTERLEUKIN-2 FOR THE TREATMENT OF AUTISM SPECTRUM DISORDERS
|
|
FR3140287B1
(fr)
|
2022-10-03 |
2025-11-21 |
Arkema France |
Procede de granulation de composes azoiques et granules obtenus
|
|
AU2023382265A1
(en)
|
2022-11-18 |
2025-10-09 |
Nanjing Novoacine Biotechnology Co., Ltd. |
Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof
|